Latest

How to understand the sharp price drop of GLP-1 weight loss drugs? Goldman Sachs: Strategic "price-for-volume", Eli Lilly has the advantage, Novo Nordisk faces pressure.

How to understand the sharp price drop of GLP-1 weight loss drugs? Goldman Sachs: Strategic "price-for-volume", Eli Lilly has the advantage, Novo Nordisk faces pressure.

Recently, Eli Lilly and Novo Nordisk reached a major agreement with the U.S. government to significantly reduce the price of GLP-1 weight-loss drugs. Goldman Sachs believes this is essentially a strategic "price-for-volume" deal; although the price cuts were sharper than expected, the tremendous potential for increased sales
Admin